Clinical Utilities of Anti-Müllerian Hormone

Russell, Nicole; Gilmore, Andrea; Roudebush, William E.

doi:10.3390/jcm11237209

Cited by 7 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the anti-müllerian hormone (AMH) undeniably performs a crucial function in the deterioration of Müllerian ducts in the initial stages of life. Several investigations have demonstrated markedly elevated levels of AMH in individuals a icted with polycystic ovary syndrome (PCOS) (21)(22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities

Irani,

Najafi,

Vesali

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age. Several studies have shown an association between PCOS and mullerian anomalies. The study aims to evaluate the prevalence of polycystic ovary morphology (PCOM) in infertile patients with uterine anomalies (septate and arcuate uterine) who attended the Royan Research Institute in Tehran (Iran) between January 2021 and December 2022. Methods: The current cross-sectional study was conducted on a total of 884 women who were experiencing infertility and referred to our Institute for 3D-hysterosonography. These women were divided into two groups: the first group consisted of 127 infertile women with uterine anomalies, while the second group included 757 infertile women without uterine anomalies. The employed sampling method was convenience and available. The necessary data were acquired from the patients' files. Subsequently, the frequency of polycystic ovary morphology (PCOM) was assessed and compared between the two groups. Result: Of the 884 patients with infertility who were evaluated, a total of 127 women (14.4%) were found to have uterine anomalies (septate and arcuate anomalies), while the remaining 757 women (85.6%) did not exhibit any such abnormalities. In the subgroup of patients with uterine anomalies, 112 women (88.1%) exhibited arcuate uterine, and 15 women (11.9%) presented with septate uterine. Our study demonstrated that the frequency of PCOM in patients with uterine anomalies was 40.9% (52 women) and in those without such anomalies was 14/7% (111 women) (p=0.0001). Conclusion: According to the study's findings, the prevalence of polycystic ovary morphology in women who have uterine anomalies is higher than in women without these anomalies.

show abstract

Section: Discussionmentioning

confidence: 99%

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities

Irani,

Najafi,

Vesali

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…the Anti-Müllerian hormone (AMH) undeniably plays a crucial role in the deterioration of the Müllerian ducts in the initial stages of life. Several investigations have demonstrated markedly elevated levels of AMH in individuals a icted with polycystic ovary syndrome (PCOS) (20)(21)(22)(23). Given the substantial heredity of PCOS and the role that AMH plays in the early degeneration of Müllerian ducts, high prenatal AMH exposure may cause both PCOS and Müllerian duct abnormalities in female offspring (11).…”

Section: Discussionmentioning

confidence: 99%

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities: a cross-sectional study

Irani,

Najafi,

Vesali

et al. 2024

Preprint

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age. Several studies have shown an association between PCOS and Mullerian anomalies. This study aimed to evaluate the prevalence of polycystic ovary morphology (PCOM) in infertile patients with uterine anomalies (septate and arcuate uterine) who attended the Royan Research Institute in Tehran (Iran) between January 2021 and December 2022. The current cross-sectional study was conducted on a total of 884 infertile women who were referred to our Institute for 3D-hysterosonography. These women were divided into two groups: the first group consisted of 127 infertile women with uterine anomalies, while the second group included 757 infertile women without uterine anomalies. Information about the participants was extracted from their medical records at the Royan Research Institute. This study demonstrated that the frequency of PCOM in patients with uterine anomalies was 40.9% (52 women) and in those without such anomalies, it was 14/7% (111 women) (p = 0.0001). According to the study's findings, the prevalence of polycystic ovary morphology in women who have uterine anomalies is greater than that in women without these anomalies.

show abstract

“…While there have been unpublished data demonstrating internal validity by the Mira monitor manufacturers, there have not been any formal studies comparing it to the gold standard of the estimated day of ovulation on ultrasound, and serum correlations need to be externally validated. These results should also be contextualized with regard to ovarian reserve with serum anti-Müllerian hormone (AMH) levels [ 36 ]. Besides hormonal variations, other key parameters of the menstrual cycle include bleeding patterns and vital sign changes.…”

Section: Introductionmentioning

confidence: 99%

Establishing a Gold Standard for Quantitative Menstrual Cycle Monitoring

Bouchard,

Yong,

Doyle-Baker

2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: The Quantum Menstrual Health Monitoring Study will measure four key reproductive hormones in the urine (follicle-stimulating hormone, FSH; estrone-3-glucuronide, E13G; luteinizing hormone, LH; and pregnanediol glucuronide, PDG) to characterize patterns that predict and confirm ovulation, referenced to serum hormones and the gold standard of the ultrasound day of ovulation in participants with regular cycles. These normal cycles will provide a reference for comparison to irregular cycles in subjects with polycystic ovarian syndrome (PCOS) and athletes. Materials and Methods: Participants will track their menstrual cycles for 3 months and be provided with an at-home urine hormone monitor (Mira monitor) to predict ovulation. The day of ovulation will be confirmed with serial ultrasounds completed in a community clinic. Urine results will be compared to serum hormone values. Other markers of menstrual health, such as bleeding patterns and temperature changes, will be determined using a customized app. Three groups will be recruited. Group 1 will include those with consistent regular cycle lengths (between 24–38 days), and will be compared to two groups with irregular cycle lengths (with increased cycle length variability and longer cycles). Group 2 will include those with polycystic ovarian syndrome (PCOS) with irregular cycles and Group 3 will include individuals participating in high levels of exercise with irregular cycles. Hypothesis: The Mira monitor quantitative urine hormone pattern will accurately correlate with serum hormonal levels and will predict (with LH) and confirm (with PDG) the ultrasound day of ovulation in those with regular cycles as well as those with irregular cycles. Rationale: Once the ultrasound validation is complete, tools like the Mira monitor with a customized app may become a new standard for at-home and remote clinical monitoring of the menstrual cycle without having to use labor-intensive follicular-tracking ultrasound or follow serum hormone changes. Conclusions: Precision monitoring of the menstrual cycle is expected to impact individuals who want to increase their menstrual health literacy and guide decisions about fertility.

show abstract

Clinical Utilities of Anti-Müllerian Hormone

Cited by 7 publications

References 39 publications

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities

A survey of the frequency of polycystic ovary morphology in infertile patients with uterine abnormalities: a cross-sectional study

Establishing a Gold Standard for Quantitative Menstrual Cycle Monitoring

Contact Info

Product

Resources

About